Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Donna Hansel

    TitleAdjunct Professor
    SchoolUniversity of California, San Diego
    Address9500 Gilman Drive #0612
    CA La Jolla 92093
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Sahu D, Lotan Y, Wittmann B, Neri B, Hansel D. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. Cancer Med. 2017 Sep; 6(9):2106-2120. PMID: 28766915.
        View in: PubMed
      2. Hau AM, Nakasaki M, Nakashima K, Krish G, Hansel D. Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition. Urol Oncol. 2017 Apr 18. PMID: 28427860.
        View in: PubMed
      3. Hansel D. The Gleason Grading System: The Approach that Changed Prostate Cancer Assessment. J Urol. 2017 Feb; 197(2S):S140-S141. PMID: 28010973.
        View in: PubMed
      4. Sahu D, Gupta S, Hau AM, Nakashima K, Leivo MZ, Searles SC, Elson P, Bomalaski JS, Casteel DE, Boss GR, Hansel D. Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2a Activity and Is Targetable by Pegylated Arginine Deiminase. Am J Pathol. 2016 Dec 09. PMID: 27979310.
        View in: PubMed
      5. Hau AM, Leivo MZ, Gilder AS, Hu JJ, Gonias SL, Hansel D. mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer. Cell Signal. 2017 Jan; 29:96-106. PMID: 27777073.
        View in: PubMed
      6. Solomon JP, Lowenthal BM, Kader AK, Parsons JK, Flaig TW, Siefker-Radtke AO, Dyrskjøt L, Hansel D. Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review? Urology. 2017 Apr; 102:7-16. PMID: 27769917.
        View in: PubMed
      7. Leivo MZ, Elson PJ, Tacha DE, Delahunt B, Hansel D. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. Pathology. 2016 Oct; 48(6):543-9. PMID: 27594510.
        View in: PubMed
      8. Hansel D, Reuter VE. Adrenal Pathology in the Adult: A Urological Pathologist's Perspective. Adv Anat Pathol. 2016 Sep; 23(5):273-84. PMID: 27438375.
        View in: PubMed
      9. Solomon JP, Hansel D. The Emerging Molecular Landscape of Urothelial Carcinoma. Surg Pathol Clin. 2016 Sep; 9(3):391-404. PMID: 27523968.
        View in: PubMed
      10. Brunsing RL, Schenker-Ahmed NM, White NS, Parsons JK, Kane C, Kuperman J, Bartsch H, Kader AK, Rakow-Penner R, Seibert TM, Margolis D, Raman SS, McDonald CR, Farid N, Kesari S, Hansel D, Shabaik A, Dale AM, Karow DS. Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI. J Magn Reson Imaging. 2017 Feb; 45(2):323-336. PMID: 27527500.
        View in: PubMed
      11. Sanfrancesco J, McKenney JK, Leivo MZ, Gupta S, Elson P, Hansel D. Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition. Arch Pathol Lab Med. 2016 Jun; 140(6):543-51. PMID: 27031776.
        View in: PubMed
      12. Gupta S, Hau AM, Al-Ahmadie HA, Harwalkar J, Shoskes AC, Elson P, Beach JR, Hussey GS, Schiemann WP, Egelhoff TT, Howe PH, Hansel D. Transforming Growth Factor-ß Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion. Am J Pathol. 2016 May; 186(5):1351-60. PMID: 26988652; PMCID: PMC4861762 [Available on 05/01/17].
      13. Solomon JP, Hansel D. Morphologic and Molecular Characteristics of Bladder Cancer. Surg Pathol Clin. 2015 Dec; 8(4):663-76. PMID: 26612220.
        View in: PubMed
      14. Ikeda S, Hansel D, Kurzrock R. Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. Cancer Treat Rev. 2015 Sep; 41(8):699-706. PMID: 26138514.
        View in: PubMed
      15. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel D, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015 May 07; 521(7550):94-8. PMID: 25924065; PMCID: PMC4501632.
      16. Solomon JP, Hansel D. Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates. Adv Anat Pathol. 2015 Mar; 22(2):102-12. PMID: 25664945.
        View in: PubMed
      17. Guin S, Pollard C, Ru Y, Ritterson Lew C, Duex JE, Dancik G, Owens C, Spencer A, Knight S, Holemon H, Gupta S, Hansel D, Hellerstein M, Lorkiewicz P, Lane AN, Fan TW, Theodorescu D. Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. J Natl Cancer Inst. 2014 Apr 03; 106(5). PMID: 24700805; PMCID: PMC4580555.
      18. Ananthanarayanan V, Pan Y, Tretiakova M, Amin MB, Cheng L, Epstein JI, Grignon DJ, Hansel D, Jimenez RE, McKenney JK, Montironi R, Oliva E, Osunkoya AO, Rao P, Reuter VE, Ro JY, Shen SS, Srigley JR, Tsuzuki T, Yao JL, Antic T, Haber M, Taxy JB, Paner GP. Influence of histologic criteria and confounding factors in staging equivocal cases for microscopic perivesical tissue invasion (pT3a): an interobserver study among genitourinary pathologists. Am J Surg Pathol. 2014 Feb; 38(2):167-75. PMID: 24145655.
        View in: PubMed
      19. Gupta S, Hau AM, Beach JR, Harwalker J, Mantuano E, Gonias SL, Egelhoff TT, Hansel D. Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion. PLoS One. 2013; 8(11):e81081. PMID: 24312263; PMCID: PMC3842329.
      20. Hansel D, Zhang Z, Petillo D, Teh BT. Gene profiling suggests a common evolution of bladder cancer subtypes. BMC Med Genomics. 2013 Oct 17; 6:42. PMID: 24134934; PMCID: PMC4015777.
      21. Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel D. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 01; 19(7):1717-28. PMID: 23403633; PMCID: PMC3626291.
      22. Zhang Z, Furge KA, Yang XJ, Teh BT, Hansel D. Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med Genomics. 2010 Dec 15; 3:58. PMID: 21159190; PMCID: PMC3022544.